SCHEMBL17501010

SCHEMBL17501010

CSc1ccc(B(O)O)c(C)n1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788696 0.78 CCR1 (0.40)
SCHEMBL489376 0.78 CCR1 (0.40)
SCHEMBL29398034 0.73 KDM4E (0.32) IDO1
Ammonia Solution, Strong SCHEMBL29136365 0.71 NOS3 (0.44) IDO1
SCHEMBL29951491 0.71 CA2 (0.32)
SCHEMBL16792339 0.70 IDO1 (0.35) IDO1
SCHEMBL6280564 0.70 IDO1 (0.43) IDO1
SCHEMBL19454605 0.70 IDO1 (0.35) IDO1
SCHEMBL15691394 0.70 IDO1 (0.35) IDO1
SCHEMBL1937542 0.70 CHRNB2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-20 US disclosed
EP-3395818-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2021-09-22 EP disclosed
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-12-10 US disclosed
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-09-15 US disclosed
EP-3395818-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2018-10-31 EP disclosed
US-20180256591-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-09-13 US disclosed
US-9993484-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-06-12 US disclosed
EP-3177619-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2018-04-25 EP disclosed
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-03 US disclosed
EP-3177619-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2017-06-14 EP disclosed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 US disclosed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 US disclosed
WO-2016020320-A1 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180256591-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS IDO1 1623/4885
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS IDO1 1623/4885
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS IDO1 1623/4885
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS IDO1 1623/4885
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS IDO1 1623/4885
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS IDO1 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.